Oxford Nanopore Prevails in Patent Ruling against Pacific Biosciences
Today the European Patent Office revoked Pacific Biosciences patent EP3045542 with claims to a single molecule sequencing process wherein two strands of DNA are linked by a connecting nucleic acid. The validity of the patent had been challenged by Oxford Nanopore.
The EPO ruled that the claims to a single molecule sequencing process were unsupported in the application and that the application only supported a template-directed synthesis sequencing method. As Pacific Biosciences were unwilling to accept this change, the patent was revoked.
The decision by the EPO is consistent with a recent decision by the International Trade Commission (ITC) to limit the claims of a related Pacific Biosciences US patent to template-directed synthesis.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CTA19.8.2019 09:02:03 CEST | Press release
CES Unveiled in Amsterdam to Showcase Tech for Good
RISO-KAGAKU-CORPORATION19.8.2019 08:02:08 CEST | Press release
RISO Unveils VALEZUS, a New Brand for the Production-printing Market
CA-VELODYNE-LIDAR,-INC.16.8.2019 14:02:11 CEST | Press release
Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense
MERZ-PHARMA16.8.2019 11:28:06 CEST | Press release
Merz Announces Key Governance Changes
FINEOS-CORPORATION16.8.2019 09:24:13 CEST | Press release
FINEOS lists on the Australian Securities Exchange
CA-GILEAD-SCIENCES15.8.2019 22:03:09 CEST | Press release
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom